AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

Loading...
Loading...
  • AbbVie Inc ABBV announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. 
  • Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. 
  • The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated an overall response rate (ORR) of 63% and a complete response (CR) rate of 39%. 
  • Related: AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study.
  • Patients in the study who were naïve to CAR T-cell therapy achieved a 69% ORR and a 42% CR, and patients who received prior CAR T-cell therapy achieved a 54% ORR and a 34% CR. 
  • After a median follow-up of 10.7 months, the median duration of response (mDOR) was estimated to be 12 months, while the mDOR among patients achieving a CR was not reached, with 89% still in CR at nine months. 
  • Epcoritamab is being co-developed by AbbVie and Genmab A/S GMAB as part of the companies' broad oncology collaboration.
  • Price Action: ABBV shares are down 1.42% at $141.11, and GMAB is down 3.18% at $27.97 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...